Glaukos Co. (NYSE:GKOS) Shares Sold by Blair William & Co. IL

Blair William & Co. IL lowered its holdings in Glaukos Co. (NYSE:GKOS) by 1.8% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 49,094 shares of the medical instruments supplier’s stock after selling 896 shares during the period. Blair William & Co. IL owned approximately 0.10% of Glaukos worth $5,810,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in GKOS. Quadrant Capital Group LLC increased its holdings in Glaukos by 54.8% during the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock worth $74,000 after purchasing an additional 329 shares during the period. GAMMA Investing LLC raised its holdings in Glaukos by 68.8% in the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after acquiring an additional 486 shares in the last quarter. Caldwell Sutter Capital Inc. raised its holdings in Glaukos by 5,860.0% in the first quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock valued at $140,000 after acquiring an additional 1,465 shares in the last quarter. Fifth Third Wealth Advisors LLC purchased a new position in Glaukos in the second quarter worth approximately $187,000. Finally, LVW Advisors LLC acquired a new position in Glaukos during the 2nd quarter worth approximately $213,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on GKOS shares. Morgan Stanley lifted their price objective on shares of Glaukos from $100.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Piper Sandler lifted their price target on Glaukos from $110.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Wells Fargo & Company increased their price objective on Glaukos from $120.00 to $135.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Truist Financial restated a “buy” rating and set a $145.00 target price (up previously from $141.00) on shares of Glaukos in a research note on Thursday, August 1st. Finally, Needham & Company LLC increased their price target on shares of Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Glaukos has an average rating of “Moderate Buy” and an average target price of $129.82.

Glaukos Price Performance

GKOS stock opened at $127.78 on Friday. The company has a current ratio of 5.48, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $6.44 billion, a P/E ratio of -44.37 and a beta of 1.03. The business has a 50 day simple moving average of $124.89 and a 200-day simple moving average of $111.54. Glaukos Co. has a twelve month low of $59.22 and a twelve month high of $136.60.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.52). The firm had revenue of $95.70 million during the quarter, compared to analysts’ expectations of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. Glaukos’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.55) EPS. As a group, equities analysts anticipate that Glaukos Co. will post -2.18 EPS for the current year.

Insider Buying and Selling

In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the sale, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the transaction, the director now owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Marc Stapley sold 6,250 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $125.93, for a total value of $787,062.50. Following the sale, the director now owns 34,076 shares of the company’s stock, valued at approximately $4,291,190.68. The disclosure for this sale can be found here. Insiders have sold a total of 41,500 shares of company stock valued at $5,099,000 over the last quarter. 6.40% of the stock is currently owned by insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.